Shares of Selecta Biosciences Inc (NASDAQ:SELB) hit a new 52-week low on Thursday . The stock traded as low as $10.26 and last traded at $11.20, with a volume of 11,806 shares. The stock had previously closed at $10.65.

SELB has been the topic of several research analyst reports. Stifel Nicolaus initiated coverage on shares of Selecta Biosciences in a research note on Monday, July 18th. They set a “buy” rating and a $23.00 price objective on the stock. Canaccord Genuity began coverage on shares of Selecta Biosciences in a research note on Monday, July 18th. They set a “buy” rating and a $20.00 price objective on the stock. Finally, Needham & Company LLC began coverage on shares of Selecta Biosciences in a research report on Monday, July 18th. They set a “buy” rating and a $28.00 target price on the stock.

The stock has a 50-day moving average price of $12.88 and a 200 day moving average price of $12.94.

In other Selecta Biosciences news, major shareholder Nanodimension Management Ltd acquired 385,000 shares of the company’s stock in a transaction on Monday, June 27th. The stock was acquired at an average price of $14.00 per share, for a total transaction of $5,390,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Amir Nashat acquired 150,000 shares of the company’s stock in a transaction on Monday, June 27th. The stock was acquired at an average price of $14.00 per share, with a total value of $2,100,000.00. The disclosure for this purchase can be found here.

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.